Trial
NCT04581824
Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
GlaxoSmithKline
Collaborators
—
Condition
Lung Cancer, Non-Small Cell
Intervention
Dostarlimab
Why stopped
Trial terminated by GSK for strategic reasons, after all participants completed treatment. This decision was not based on a safety concern
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-08-08